Tackling Eosinophilic Disorders

Join us on Sunday, March 1, 2026, in Philadelphia, PA or via live stream! Click below for more information and to register.

This program is not sponsored or programmed by the AAAAI.

This program is not certified for continuing education credit. The content and opinions expressed are those of the sponsor and/or presenter(s) and are not necessarily those of the AAAAI.

There is no fee to attend this Non-CME Educational Program.

Program Overview

Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are both rare types of eosinophilic disorders. Diagnosis and management of these disorders is challenging due to their complex and overlapping pathologic features and heterogeneous systemic involvement. Both disorders carry substantial risks of morbidity and mortality due to delayed diagnosis and inadequate treatment. Interleukin (IL)-5 is a key driver of pathophysiology; therapies targeting IL-5 or the IL-5 receptor are a mainstay of treatment. In this Mechanisms to Medicine symposium, an expert panel will discuss key pathophysiologic mechanisms in EGPA and HES with a focus on clinical implications for diagnosis and treatment.